TWD
NAMS icon

True Wealth Design’s NewAmsterdam Pharma NAMS Stock Holding History

True Wealth Design’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$712 Hold
21
– – ﹤0.01% 2094
2026
Q1 		$673 Hold
21
– – ﹤0.01% 1942
2025
Q4 		$737 Hold
21
– – ﹤0.01% 1825
2025
Q3 		$598 Hold
21
– – ﹤0.01% 1950
2025
Q2 		$381 Buy
21
+19
+950% +$347 ﹤0.01% 1847
2025
Q1 		$41 Buy
+2
New +$44 ﹤0.01% 2434

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

True Wealth Design's NAMS Position: Q2 2026 in Review

True Wealth Design held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 21 shares worth $712. The position accounts for ﹤0.01% of the portfolio, ranked #2094.

True Wealth Design first reported a position in NAMS in Q1 2025 and has held it in 6 quarters since. The position peaked at $737 in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • True Wealth Design held 21 shares of NewAmsterdam Pharma worth $712 as of Q2 2026.
  • True Wealth Design left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2094 holding.
  • True Wealth Design first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 6 quarters since.
  • True Wealth Design's NewAmsterdam Pharma position peaked at $737 in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.